| HOME >> BIOLOGY >> TECHNOLOGY |
Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
CLINICAL PIPELINE OVERVIEW
Osteoporosis pipeline
The osteoporosis pipeline remains robust
Companies are focusing on developing anabolics as competition in the antiresorptive market increases
Mechanism of action
Late-stage development compounds recently discontinued
TARGET PRODUCT PROFILE
Comparator therapies
Fosamax (alendronate; Merck & Co)
Target product profile versus current level of attainment
CLINICAL TRIAL DESIGN IN OSTEOPOROSIS
Preclinical trials
Two different animal species tests are required by both the FDA and EMA
Preclinical trial design should reflect the clinical indication
Clinical trials
The FDA and EMA have different patient inclusion requirements for osteoporosis trials
Clinical endpoints
Future developments in clinical trial design
Trial endpoints unlikely to change
INNOVATIVE EARLY-STAGE APPROACHES
New targets for osteoporosis treatments
Targets
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |